Maze Therapeutics, Inc.

MAZEdata completeness 75%2 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'interestExpense'

The thesis, from the filings

Maze Therapeutics, Inc. earns about -63% on invested capital, but has diluted owners by 1474% over 2 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2024	FY 2025
Revenue	$167.5M¹	—
Net income	$52.2M²	−$131.1M²
Operating cash flow	$76M³	−$111.9M³
Capital expenditure	$1.15M⁴	$794,000⁴
Free cash flow (derived)	$74.8M³	−$112.7M³
Total debt	—	—
Cash & equivalents	$196.8M⁵	$189.2M⁵
Diluted shares	2.7M	43.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

$82.6

your share of equity

Profit it earned you last year

−$30.51

Free cash flow it threw off

−$26.23

Debt you’d be carrying

—

10 shares is a claim on $82.6 of net worth that earned you −$30.51 and generated −$26.23 of cash last year.

iii. Is this a good business?

Moat signal · return on invested capital

-63% avg · 2y

FY24 —FY25 -63%

It earned an average -63% on invested capital over 2 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+1474% shares · 2y

Share count is up 1474% over 2 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 2 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 2 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

only 2 years of net income (need ≥3)

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2024-12-31 · accession 0001193125-26-122778 (RevenueFromContractWithCustomerExcludingAssessedTax)
10-K · period ending 2024-12-31 · accession 0001193125-26-122778 (NetIncomeLoss)
10-K · period ending 2024-12-31 · accession 0001193125-26-122778 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-12-31 · accession 0001193125-26-122778 (PaymentsToAcquirePropertyPlantAndEquipment)
10-K · period ending 2024-12-31 · accession 0001193125-26-122778 (CashAndCashEquivalentsAtCarryingValue)